Diabetic Obesity, often referred to as "diabesity," is a condition where an individual has both obesity and type 2 diabetes. It is a complex metabolic condition where excess body fat contributes to insulin resistance, exacerbating type 2 diabetes.

Diabetic obesity is a growing health concern worldwide, affecting millions of people and posing significant challenges to metabolic health. This condition combines the complexities of diabetes with metabolic syndrome (Met S) associated with obesity, leading to a higher risk of complications.

Control Diabetic Obesity with BYZEPTA^TM

A novel approach to counteract this metabolic disease

Recent evidence demonstrates a strong association between Met S and Diabetic Obesity among Indian/ Asian Population making them more prone to Visceral Adiposity, and lower skeletal mass due to GLP-1 and UCP-1 downregulation being the primary root causes for the disease progression.

BYZEPTA^TM upregulates GLP-1 and UCP-1 Expression

Upregulation of GLP-1 and UCP-1 counter insulin resistance & visceral adiposity which contribute to decrease in progression of the disease

Endogenous expression of GLP-1 and UCP-1 leads to improved Insulin sensitivity, Glucose uptake and reduced carbohydrate craving alongside increase in Thermogenesis and Browning of White Adipose Tissue (WAT) leading to regression of Diabetic Obesity